CD8A and neoplasm: cDC1 and CD8+ T cells are primary components in the TME of effective adaptive anti-tumor responses, especially upon ICB immunotherapy; their possible involvement in promoting development of immune-resistant dormant tumor cells responsible for late arising metastatic lesions in patients with apparent remissions is thus a critical issue to examine, as it could reveal a duality to the effects of immunotherapy.